journal
https://read.qxmd.com/read/36907702/corrigendum-to-chemotherapy-in-patients-with-localized-angiosarcoma-of-any-site-a-retrospective-european-study-eur-j-cancer-171-2022-183-192
#1
Fabio Conforti, Alessandro Gronchi, Nicholas Penel, Robin L Jones, Javier M Broto, Isabella Sala, Vincenzo Bagnardi, Andrea Napolitano, Laura Pala, Elisabetta Pennacchioli, Chiara Catania, Paola Queirolo, Giovanni Grigani, Alessandra Merlini, Silvia Stacchiotti, Alessandro Comandone, Bruno Vincenzi, Vittorio Quagliuolo, Alexia Bertuzzi, Antonella Boglione, Elena Palassini, Giacomo G Baldi, Jean-Yves Blay, Thomas Ryckewaert, Maud Toulmonde, Antoine Italiano, Axel Le Cesne, Isabelle Ray-Coquard, Josefina Cruz, Carmen N Hernández-León, Javier M Trufero, David da Silva Moura, Nadia H Muñiz, Tommaso De Pas
No abstract text is available yet for this article.
March 10, 2023: European Journal of Cancer
https://read.qxmd.com/read/36868971/corrigendum-to-preclinical-evaluation-of-drug-combinations-identifies-co-inhibition-of-bcl-2-xl-w-and-mdm2-as-a-potential-therapy-in-uveal-melanoma-eur-j-cancer-126-2020-93-103
#2
Didier Decaudin, Estelle Frisch Dit Leitz, Fariba Nemati, Malcy Tarin, Adnan Naguez, Mohamed Zerara, Benjamin Marande, Raquel Vivet-Noguer, Ensar Halilovic, Claire Fabre, Aart Jochemsen, Sergio Roman-Roman, Samar Alsafadi
No abstract text is available yet for this article.
March 1, 2023: European Journal of Cancer
https://read.qxmd.com/read/36917924/immunogenetic-variations-predict-immune-related-adverse-events-for-pd-1-pd-l1-inhibitors
#3
JOURNAL ARTICLE
Zhaodan Xin, Liting You, Feifei Na, Jin Li, Min Chen, Jiajia Song, Ling Bai, Jie Chen, Juan Zhou, Binwu Ying
BACKGROUND: PD-1/PD-L1 inhibitors have brought remarkable benefits but can cause profound immune-related adverse events (irAEs). The host immunogenetic background is likely to play a role in irAE susceptibility. In this study, we aimed to identify potential immunogenetic biomarkers to predict irAEs. METHODS: Patients with solid tumours receiving PD-1/PD-L1 blockade were recruited and followed up. Genes considered pivotal contributors to tumour-immunity and autoimmune diseases were screened out via protein-protein interaction network and Cytoscape...
February 23, 2023: European Journal of Cancer
https://read.qxmd.com/read/36931075/adjuvant-durvalumab-after-concurrent-chemoradiotherapy-for-patients-with-unresectable-stage-iii-nsclc-harbouring-uncommon-genomic-alterations
#4
JOURNAL ARTICLE
Francesco Cortiula, Dirk De Ruysscher, Michelle Steens, Robin Wijsman, Anthonie van der Wekken, Martina Alberti, Lizza E L Hendriks
Adjuvant durvalumab is the standard of care for patients with stage III unresectable non-small cell lung cancer (NSCLC), without progression after concurrent chemo-radiation (CCRT). Patients with stage III NSCLC harbouring epidermal growth factor receptor (EGFR) mutations and anaplastic lymphoma kinase rearrangements do not seem to benefit from durvalumab. Data are lacking about patients harbouring other driver genomic alterations (dGA). We performed a multicentre (N = 4, Netherlands and Italy) retrospective study including consecutive patients with unresectable stage III NSCLC and treated with CCRT-with or without adjuvant durvalumab-between 2016 and 2022...
February 21, 2023: European Journal of Cancer
https://read.qxmd.com/read/36898234/letter-re-metabolic-switch-in-cancer-survival-of-the-fittest-targeting-metabolic-pathways-in-cancer-a-double-edged-sword
#5
LETTER
Chen-Xiong Hsu, Pei-Wei Shueng
No abstract text is available yet for this article.
February 20, 2023: European Journal of Cancer
https://read.qxmd.com/read/36931074/survival-and-immunotoxicities-in-association-with-sex-specific-body-composition-patterns-of-cancer-patients-undergoing-immune-checkpoint-inhibitor-therapy-a-systematic-review-and-meta-analysis
#6
REVIEW
Paul Trinkner, Sophie Günther, Ina Monsef, Eva Kerschbaum, Michael von Bergwelt-Baildon, David M Cordas Dos Santos, Sebastian Theurich
BACKGROUND: Imbalanced body composition is mechanistically connected to dysregulated immune activities. Whether overweight/obesity or sarcopenia has an impact on treatment results in cancer patients undergoing immune checkpoint inhibitor (ICI) therapy is currently under debate. We aimed to answer if survival rates and occurrence of immune-related adverse events (irAEs) were different in obese or sarcopenic patients. METHODS: A systematic search was conducted in PubMed, Embase and CENTRAL for all records published until July 2022 using specific search terms for body composition in combination with terms for ICI regimens...
February 18, 2023: European Journal of Cancer
https://read.qxmd.com/read/36907021/impact-of-immune-checkpoint-inhibitors-and-targeted-therapy-on-health-related-quality-of-life-of-people-with-stage-iii-and-iv-melanoma-a-mixed-methods-systematic-review
#7
REVIEW
Julia Lai-Kwon, Andrisha-Jade Inderjeeth, Karolina Lisy, Shahneen Sandhu, Claudia Rutherford, Michael Jefford
BACKGROUND: Immune checkpoint inhibitors (ICI) and targeted therapies (TT) have significantly improved disease control and survival in people with stage III and IV cutaneous melanoma. Understanding the impact of therapy on health-related quality of life (HRQL) is vital for treatment decision-making and determining targets for supportive care intervention. We conducted a mixed-methods systematic review to synthesise the impact of ICIs and TT on all domains of HRQL in these populations...
February 18, 2023: European Journal of Cancer
https://read.qxmd.com/read/36933518/association-between-endocrine-therapy-and-cognitive-decline-in-older-women-with-early-breast-cancer-findings-from-the-prospective-climb-study
#8
JOURNAL ARTICLE
Joosje C Baltussen, Marloes G M Derks, Annelieke A Lemij, Nienke A de Glas, Marta Fiocco, Eugenie M H Linthorst-Niers, Annelie J E Vulink, Leander van Gerven, Onno R Guicherit, Thijs van Dalen, Jos W S Merkus, Titia E Lans, Carmen C van der Pol, Simon P Mooijaart, Johanneke E A Portielje, Gerrit-Jan Liefers
INTRODUCTION: Studies investigating the long-term effects of breast cancer treatment on cognition in older women with breast cancer are lacking, even though preserving cognition is highly valued by the older population. Specifically, concerns have been raised regarding the detrimental effects of endocrine therapy (ET) on cognition. Therefore, we investigated cognitive functioning over time and predictors for cognitive decline in older women treated for early breast cancer. METHODS: We prospectively enrolled Dutch women aged ≥70 years with stage I-III breast cancer in the observational CLIMB study...
February 17, 2023: European Journal of Cancer
https://read.qxmd.com/read/36913832/primary-tumour-side-as-a-driver-for-treatment-choice-in-ras-wild-type-metastatic-colorectal-cancer-patients-a-systematic-review-and-pooled-analysis-of-randomised-trials
#9
JOURNAL ARTICLE
Daniele Rossini, Alessandra Boccaccino, Martina Carullo, Carlotta Antoniotti, Giovanni Dima, Paolo Ciracì, Federica Marmorino, Roberto Moretto, Gianluca Masi, Chiara Cremolini
BACKGROUND: Retrospective subgroup analyses of previous trials in the first-line therapy of RAS wt metastatic colorectal cancer (mCRC) suggested a predictive impact of primary tumour side on the efficacy of anti-epidermal growth factor receptor (EGFR) agents. Recently, new head-to-head trials of doublets/bevacizumab versus doublets/anti-EGFR, PARADIGM and CAIRO5 were presented. PATIENTS AND METHODS: We searched for phase II and III trials comparing doublet chemotherapy plus an anti-EGFR or bevacizumab as the first-line treatment for RAS wt mCRC patients...
February 17, 2023: European Journal of Cancer
https://read.qxmd.com/read/36917923/eif4f-translation-initiation-complex-a-predictive-marker-of-response-to-immunotherapy-in-mucosal-melanoma
#10
LETTER
Antoine Moya-Plana, Carine Ngo, Emilie Lanoy, Stephan Vagner, Caroline Robert
No abstract text is available yet for this article.
February 16, 2023: European Journal of Cancer
https://read.qxmd.com/read/36913833/the-response-rate-by-tumour-type-for-tissue-agnostic-approved-drugs
#11
LETTER
Alyson Haslam, Vinay Prasad
No abstract text is available yet for this article.
February 15, 2023: European Journal of Cancer
https://read.qxmd.com/read/36905771/clinical-efficacy-of-fulvestrant-versus-exemestane-as-first-line-therapies-for-chinese-postmenopausal-oestrogen-receptor-positive-human-epidermal-growth-factor-receptor-2-advanced-breast-cancer-friend-study
#12
JOURNAL ARTICLE
Jiayu Wang, Li Cai, Yanqiu Song, Tao Sun, Zhongsheng Tong, Yuee Teng, Huiping Li, Quchang Ouyang, Qianjun Chen, Shude Cui, Yongmei Yin, Ning Liao, Qiang Sun, Jifeng Feng, Xiaojia Wang, Binghe Xu
AIM: To compare the efficacies of exemestane and fulvestrant as first-line monotherapies for postmenopausal Chinese women having advanced oestrogen-receptor positive (ER+)/ human epidermal growth factor receptor 2 (HER2)-breast cancer (ER+/HER2- ABC) after a previous treatment for ≥2 years with an adjuvant non-steroidal aromatase inhibitor. METHODS: In this randomised, open-label, multi-centre, parallel-controlled phase 2 FRIEND study, 145 postmenopausal ER+/HER2- ABC patients were assigned into fulvestrant (500 mg on days 0, 14 and 28, and then at every 28 ± 3 days, n = 77) and exemestane (25 mg/day, n = 67) groups...
February 15, 2023: European Journal of Cancer
https://read.qxmd.com/read/36898232/proton-pump-inhibitors-and-antibiotics-adversely-effect-the-efficacy-of-nivolumab-in-patients-with-recurrent-or-metastatic-squamous-cell-carcinoma-of-the-head-and-neck
#13
JOURNAL ARTICLE
Akihisa Wada, Tomohiro Enokida, Susumu Okano, Masanobu Sato, Hideki Tanaka, Yuri Ueda, Takao Fujisawa, Naohiro Takeshita, Nobukazu Tanaka, Makoto Tahara
BACKGROUND: Several reports have shown that the use of proton pump inhibitors (PPIs) and antibiotics (Abx) can reduce the efficacy of immune checkpoint inhibitors in various cancers. To date, however, the association of immune checkpoint inhibitors with PPI and/or Abx in patients with recurrent or metastatic head and neck squamous cell carcinoma (R/M SCCHN) has not been reported. METHODS: We retrospectively reviewed patients with platinum-refractory R/M SCCHN treated with nivolumab from May 2017 and March 2020 in our institute...
February 15, 2023: European Journal of Cancer
https://read.qxmd.com/read/36889038/faecal-haemoglobin-concentration-predicts-all-cause-mortality
#14
JOURNAL ARTICLE
Ulrik Deding, Lasse Kaalby, Robert Steele, Issam Al-Najami, Morten Kobaek-Larsen, Eva Plantener, Jeppe B Madsen, Jonna S Madsen, Thomas Bjørsum-Meyer, Gunnar Baatrup
BACKGROUND: Population-based screening for colorectal cancer by a faecal immunochemical test (FIT) is recommended by the European Union. Detectable faecal haemoglobin can indicate colorectal neoplasia as well as other conditions. A positive FIT predicts an increased risk of death from colorectal cancer but might also predict an increased risk of all-cause mortality. METHODS: A cohort of screening participants was followed using the Danish National Register of Causes of Death...
February 15, 2023: European Journal of Cancer
https://read.qxmd.com/read/36893711/olympiad-extended-follow-up-for-overall-survival-and-safety-olaparib-versus-chemotherapy-treatment-of-physician-s-choice-in-patients-with-a-germline-brca-mutation-and-her2-negative-metastatic-breast-cancer
#15
JOURNAL ARTICLE
Mark E Robson, Seock-Ah Im, Elzbieta Senkus, Binghe Xu, Susan M Domchek, Norikazu Masuda, Suzette Delaloge, Nadine Tung, Anne Armstrong, Mike Dymond, Anitra Fielding, Allison Allen, Pierfranco Conte
BACKGROUND: In the Phase III OlympiAD study, olaparib significantly prolonged progression-free survival versus chemotherapy treatment of physician's choice (TPC) in patients with germline BRCA-mutated (gBRCAm), human epidermal growth factor receptor 2-negative metastatic breast cancer (mBC). In the final pre-specified analysis (64% maturity), median overall survival (OS) was 19.3 months for olaparib and 17.1 months for TPC (P = 0.513). Post-hoc extended follow-up, 25.7 months longer than previously reported for OS, is reported...
February 14, 2023: European Journal of Cancer
https://read.qxmd.com/read/36797103/letter-re-survival-trends-in-solid-cancers-in-the-nordic-countries-through-50%C3%A2-years-proper-referencing-is-necessary-when-using-free-of-charge-online-cancer-statistics-resources-like-nordcan
#16
LETTER
https://read.qxmd.com/read/36870191/letter-re-toxicities-associated-with-chemotherapy-regimens-containing-a-fluoropyrimidine-a-real-life-evaluation-in-france
#17
LETTER
Bernard Guennebaud, Alain Rivoire
No abstract text is available yet for this article.
February 13, 2023: European Journal of Cancer
https://read.qxmd.com/read/36792396/response-to-letter-entitled-re-survival-trends-in-solid-cancers-in-the-nordic-countries-through-50%C3%A2-years
#18
LETTER
Kari Hemminki
No abstract text is available yet for this article.
February 13, 2023: European Journal of Cancer
https://read.qxmd.com/read/36905770/multicentre-real-world-data-of-ramucirumab-plus-docetaxel-after-combined-platinum-based-chemotherapy-with-programmed-death-1-blockade-in-advanced-non-small-cell-lung-cancer-nej051-reactive-study
#19
JOURNAL ARTICLE
Atsushi Nakamura, Ou Yamaguchi, Keita Mori, Keita Miura, Motohiro Tamiya, Tomohiro Oba, Noriko Yanagitani, Hideaki Mizutani, Takashi Ninomiya, Tomosue Kajiwara, Kentaro Ito, Akihiko Miyanaga, Daisuke Arai, Hiroaki Kodama, Kunihiko Kobayashi, Kyoichi Kaira
BACKGROUND: Ramucirumab plus docetaxel (RD) is a promising treatment for previously treated advanced non-small cell lung cancer (NSCLC). However, its clinical significance after platinum-based chemotherapy plus programmed death-1 (PD-1) blockade remains unclear. RESEARCH QUESTION: What is the clinical significance of RD as a second-line treatment after the failure of chemo-immunotherapy in NSCLC? STUDY DESIGN AND METHODS: In this multicentre retrospective study, 288 patients with advanced NSCLC who received RDas second-line therapy after platinum-based chemotherapy plus PD-1 blockade, at 62 Japanese institutions from January 2017 to August 2020, were included...
February 11, 2023: European Journal of Cancer
https://read.qxmd.com/read/36898233/overall-survival-with-neratinib-after-trastuzumab-based-adjuvant-therapy-in-her2-positive-breast-cancer-extenet-a-randomised-double-blind-placebo-controlled-phase-3-trial
#20
JOURNAL ARTICLE
Frankie A Holmes, Beverly Moy, Suzette Delaloge, Stephen K L Chia, Bent Ejlertsen, Janine Mansi, Hiroji Iwata, Michael Gnant, Marc Buyse, Carlos H Barrios, Tajana Silovski, Robert Šeparović, Anna Bashford, Angel Guerrero Zotano, Neelima Denduluri, Debra Patt, Erhan Gokmen, Ira Gore, John W Smith, Sibylle Loibl, Norikazu Masuda, Zorica Tomašević, Katarina Petráková, Daniel DiPrimeo, Alvin Wong, Miguel Martin, Arlene Chan
BACKGROUND: ExteNET showed that neratinib, an irreversible pan-HER tyrosine kinase inhibitor, given for 1 year after trastuzumab-based therapy significantly improved invasive disease-free survival in women with early-stage HER2-positive breast cancer. We report the final analysis of overall survival in ExteNET. METHODS: In this international, randomised, double-blind, placebo-controlled, phase 3 trial, women aged 18 years or older with stage 1-3c (amended to stage 2-3c) HER2-positive breast cancer who had completed neoadjuvant and adjuvant chemotherapy plus trastuzumab were eligible...
February 10, 2023: European Journal of Cancer
journal
journal
30413
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.